| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a9fbfeba067df93dd1d2b4417267540f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-06139 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 |
| filingDate |
2000-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2003-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5b3593bfa3f388473b3fc76ea6257ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93fdca3454ec6cd8cb976c3e10f4055b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d047338d6102ecb83552875bab09a684
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4da9f2a43503b4b6190d5987142c6e11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e231cceedbb8142dc2ba2c8d6764802e |
| publicationDate |
2003-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-6506754-B1 |
| titleOfInvention |
Non-covalent thrombin inhibitors |
| abstract |
The present invention provides compounds which have a pyrazinone or pyridinone ring at P3 and which feature a six member heterocyclic ring having two ring nitrogen atoms and the remainder of the ring atoms carbon atoms at P1. These compounds have biological activity as active and potent inhibitors of thrombin. Their pharmaceutically acceptable salts, pharmaceutical compositions thereof and methods of using these compounds and pharmaceutical compositions comprising these compounds as therapeutic agents for treatment of disease states in mammals which are characterized by abnormal thrombosis are also described. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004058688-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7119094-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004186060-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7019019-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005148631-A1 |
| priorityDate |
2000-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |